[River Vision’s] development-stage medicine, teprotumumab (RV001) [is] a fully human monoclonal antibody (mAb) currently in development for Thyroid Eye Disease (TED), a rare, autoimmune inflammatory disorder.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”